Manos Perros

3.3k total citations · 1 hit paper
35 papers, 2.5k citations indexed

About

Manos Perros is a scholar working on Infectious Diseases, Virology and Immunology. According to data from OpenAlex, Manos Perros has authored 35 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 21 papers in Virology and 12 papers in Immunology. Recurrent topics in Manos Perros's work include HIV Research and Treatment (21 papers), HIV/AIDS drug development and treatment (20 papers) and Immune Cell Function and Interaction (9 papers). Manos Perros is often cited by papers focused on HIV Research and Treatment (21 papers), HIV/AIDS drug development and treatment (20 papers) and Immune Cell Function and Interaction (9 papers). Manos Perros collaborates with scholars based in United Kingdom, United States and France. Manos Perros's co-authors include Mike Westby, Patrick Dorr, Julie Mori, Caroline Smith‐Burchnell, Anthony Wood, Rob Webster, Blanda Stammen, Duncan Armour, Carolyn Napier and Paul Griffin and has published in prestigious journals such as Science, Journal of Virology and Journal of Medicinal Chemistry.

In The Last Decade

Manos Perros

35 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

2005 909 citations Patrick Dorr, Mike Westby et al. profile →

Peers

Countries citing papers authored by Manos Perros

Since Specialization

Citations

This map shows the geographic impact of Manos Perros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manos Perros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manos Perros more than expected).

Fields of papers citing papers by Manos Perros

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manos Perros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manos Perros. The network helps show where Manos Perros may publish in the future.

Co-authorship network of co-authors of Manos Perros

This figure shows the co-authorship network connecting the top 25 collaborators of Manos Perros. A scholar is included among the top collaborators of Manos Perros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manos Perros. Manos Perros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691) 2011 ·Clinical Pharmacology & Therapeutics ·Mark Fidock, (unknown), Carl Laxton, (unknown), (unknown), (unknown), Peter Colman, Vinay Kumar, (unknown), Katherine Wright, Subasree Srinivasan, Khurram Rana, Charles Craig, Nigel Horscroft, Manos Perros, Michael Westby, Robert O. Webster, Elna van der Ryst	64
2	Disease-Modifying Therapeutic Concepts for HIV in the Era of Highly Active Antiretroviral Therapy 2011 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Scott L. Butler, Hernán Valdez, Michael Westby, Manos Perros, Carl H. June, Jeffrey M. Jacobson, Yves Lévy, David A. Cooper, Daniel C. Douek, Michael M. Lederman, Pablo Tebas	17
3	HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention 2010 ·PLoS Pathogens ·Wade Blair, Chris Pickford, S.L. Irving, David G. Brown, Marie Anderson, Richard Bazin, Joan Cao, Giuseppe Ciaramella, Jason Isaacson, Lynn Jackson, (unknown), Anne Kjerrström, James A. Nieman, Amy K. Patick, Manos Perros, Andrew D. Scott, Kevin Whitby, Hua Wu, Scott L. Butler	241
4	Discovery of a small molecule inhibitor through interference with the gp120–CD4 interaction 2009 ·Bioorganic & Medicinal Chemistry Letters ·D. H. Williams, (unknown), David R. Fenwick, Juin Fok‐Seang, Iain Gardner, Duncan A. Hay, (unknown), Donald S. Middleton, Charles E. Mowbray, Tanya Parkinson, Manos Perros, (unknown), (unknown), Amy Randall, (unknown), Peter T. Stephenson, Thien-Duc Tran, (unknown)	8
5	Chapter 2 CCR5 Pharmacology Methodologies and Associated Applications 2009 ·Methods in enzymology on CD-ROM/Methods in enzymology ·(unknown), Sarah Able, Paul Griffin, (unknown), Ian James, Malcolm Macartney, (unknown), James E. Mills, Carolyn Napier, Iva Navrátilová, Manos Perros, (unknown), (unknown), Elna van der Ryst, Mike Westby, Patrick Dorr	13
6	Design and optimisation of potent gp120-CD4 inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·Thien-Duc Tran, (unknown), (unknown), David R. Fenwick, Juin Fok‐Seang, Iain Gardner, Duncan A. Hay, Manos Perros, (unknown), Donald S. Middleton, Tanya Parkinson, (unknown), (unknown), Amy Randall, Peter T. Stephenson, (unknown), D. H. Williams	8
7	Pyrazole NNRTIs 1: Design and initial optimisation of a novel template 2009 ·Bioorganic & Medicinal Chemistry Letters ·Charles E. Mowbray, Catherine Burt, Romuald Corbau, Manos Perros, (unknown), Paul A. Stupple, Rob Webster, Anthony Wood	30
8	Pyrazole NNRTIs 3: Optimisation of physicochemical properties 2009 ·Bioorganic & Medicinal Chemistry Letters ·Charles E. Mowbray, Romuald Corbau, Michael L. Hawes, Lyn H. Jones, James E. Mills, Manos Perros, Matthew D. Selby, Paul A. Stupple, Rob Webster, Anthony Wood	24
9	Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate 2009 ·Bioorganic & Medicinal Chemistry Letters ·Charles E. Mowbray, Catherine Burt, Romuald Corbau, (unknown), Michael L. Hawes, Manos Perros, (unknown), David A. Price, (unknown), Matthew D. Selby, Paul A. Stupple, Rob Webster, Anthony Wood	91
10	CCR5 inhibitors in HIV-1 therapy 2008 ·Expert Opinion on Drug Discovery ·Patrick Dorr, Manos Perros	14
11	Overcoming hERG Affinity in the Discovery of Maraviroc; A CCR5 Antagonist for the Treatment of HIV 2008 ·Current Topics in Medicinal Chemistry ·David A. Price, Duncan Armour, Marcel de Groot, Derek J. Leishman, Carolyn Napier, Manos Perros, Blanda Stammen, Anthony Wood	11
12	Optimization of 5‐Aryloxyimidazole Non‐Nucleoside Reverse Transcriptase Inhibitors 2008 ·ChemMedChem ·Lyn H. Jones, (unknown), Romuald Corbau, Duncan A. Hay, Donald S. Middleton, Charles E. Mowbray, (unknown), Manos Perros, Amy Randall, (unknown), Rob Webster, Mike Westby, David J. Williams	8
13	Lack of alternative coreceptor use by pediatric HIV-1 R5 isolates for infection of primary cord or adult peripheral blood mononuclear cells 2007 ·Archives of Virology ·(unknown), Patrick Dorr, Manos Perros, (unknown), Jean Leif, Katherine Luzuriaga, Paul R. Clapham	3
14	An inhibitor of the epidermal growth factor receptor function does not affect the ability of human papillomavirus 11 to form warts in the xenografted immunodeficient mouse model 2007 ·Antiviral Research ·Tanya Parkinson, Mary K. Howett, Patricia A. Welsh, Susan D. Patrick, Elizabeth Neely, (unknown), Vincent A. Pollack, Leslie R. Pustilnik, (unknown), Manos Perros	2
15	The Discovery of CCR5 Receptor Antagonists for the Treatment of HIV Infection: Hit‐to‐Lead Studies 2006 ·ChemMedChem ·Duncan Armour, Marcel J. de Groot, Martin P. Edwards, Manos Perros, David A. Price, Blanda Stammen, Anthony Wood	17
16	Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc 2006 ·Bioorganic & Medicinal Chemistry Letters ·David A. Price, Duncan Armour, Marcel de Groot, Derek J. Leishman, Carolyn Napier, Manos Perros, Blanda Stammen, Anthony Wood	49
17	Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: Effects of viral diversity, target cell and receptor density 2005 ·Antiviral Research ·(unknown), Paul J. Peters, Wendy Sullivan, Patrick Dorr, Manos Perros, Paul R. Clapham	23
18	Development and Automation of a 384-Well Cell Fusion Assay to Identify Inhibitors of CCR5/CD4-Mediated HIV Virus Entry 2004 ·SLAS DISCOVERY ·(unknown), (unknown), (unknown), (unknown), (unknown), Paul M. Hayter, (unknown), (unknown), (unknown), Manos Perros, Giuseppe Ciaramella, A. Sewing, Christine A. Williams	29
19	5th Antiviral Drug Discovery & Development Summit 2004 ·Expert Opinion on Investigational Drugs ·Wade Blair, Manos Perros	3
20	Cruciform structure of a DNA motif of parvovirus minute virus of mice (prototype strain) involved in the attenuation of gene expression 1994 ·Journal of General Virology ·Manos Perros, (unknown), Francis Dupont, Jean-Marc Vanacker, Jean Rommelaere	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact